<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139815</url>
  </required_header>
  <id_info>
    <org_study_id>103420</org_study_id>
    <nct_id>NCT00139815</nct_id>
    <nct_alias>NCT01352169</nct_alias>
  </id_info>
  <brief_title>Michelangelo - Oasis 5</brief_title>
  <official_title>An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Organon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives

      PRIMARY OBJECTIVE: To evaluate whether fondaparinux is at least as effective as or superior
      to enoxaparin in preventing death, myocardial infarction or refactory ischemia up to Day 9 in
      the acute treatment of patients with unstable angina/non ST-segment elevation myocardial
      infarction concurrently managed with standard medical therapy.

      SECONDARY OBJECTIVE: If non inferiority of fondaparinux is established on initial statistical
      analysis in a second step, superiority of fondaparinux to enoxaparin will be evaluated
      statistically.

        -  To determine whether fondaparinux is superior to enoxaparin in reducing death or MI at
           Day 9

        -  To determine whether fondaparinux is superior to enoxaparin in reducing major bleeding
           events up to Day 9

        -  To determine whether the relative effect on the primary end point of fondaparinux versus
           enoxaparin is sustained at Day 14, Day 30, Day 90 and Day 180

      Study Drug: Patients will be randomized to receive either:

        -  Fondaparinux 2.5 mg once and placebo-enoxaparin twice daily by subcutaneous injection or

        -  Enoxaparin (1mg/kg) twice and fondaparinux-placebo once daily by subcutaneous injection

      Duration of Therapy:

        -  Fondaparinux 2.5mg daily for 8 days or hospital discharge (whichever is earlier)

        -  Enoxaparin 1mg/kg b.i.d. x 2-8 days or until clinically stable.

        -  Patients should receive an ASA and all other standard medical therapies.

      Substudy:

        -  A substudy comparing routine early coronary angiography immediately or as soon as
           possible (but no later than 24 hours after randomization) and intervention versus
           delayed (&gt;48 hrs) coronary angiography and intervention.

      Primary Outcome: The first occurence of any component of the following composite up to Day 9:

        -  Death

        -  Myocardial Infarction

        -  Refractory Ischemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, double-dummy, randomized, parallel-group, controlled trial to compare
      the safety and efficacy of fondaparinux and enoxaparin in subjects with UA/NSTEMI (unstable
      angina/non ST segment myocardial infarction). Study drug (s.c.) was started immediately
      following randomization; subjects received fondaparinux 2.5mg once daily s.c for 8 days or
      until hospital discharge, if earlier, or enoxaparin 1mg/kg twice daily s.c for 2 to 8 days or
      until clinically stable. In subjects with creatinine clearance between 20mL/min and 30mL/min,
      enoxaparin was administered as 1mg/kg once daily. In addition to study drug, subjects were to
      receive standard medical care, including interventions (PCI [percutaneous coronary
      intervention] or coronary artery bypass graft surgery [CABG]).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death, myocardial infarction or refractory</measure>
    <time_frame>up to and including Day 9</time_frame>
    <description>first occurrence of any component of death, myocardial infarction or</description>
  </primary_outcome>
  <primary_outcome>
    <measure>major bleeding</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>incidence of adjudicated major bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death, myocardial infarction or refractory</measure>
    <time_frame>up to Day 9, Day 14, Day 30,</time_frame>
    <description>Incidence of the individual components of death, myocardial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>up to and including Day 14, Day</time_frame>
    <description>incidence of adjudicated major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any bleeding (major or minor)</measure>
    <time_frame>up to and including Day 9, Day</time_frame>
    <description>Any bleeding (major or minor) as reported by the investigator as</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding complications</measure>
    <time_frame>up to and including Day 9, Day</time_frame>
    <description>Severe bleeding complications according to modified thrombolysis in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, myocardial infarction</measure>
    <time_frame>up to Days 9, 14, 30, 90 and</time_frame>
    <description>composite of death, myocardial infarction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20078</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable</description>
    <arm_group_label>Fondaparinux</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <description>enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting or admitted to hospital with symptoms suspected to represent an
             acute coronary syndrome.

          -  Able to randomize within 24 hours of the onset of the most recent episode of symptoms.

          -  At least one of the following additional criteria: (1) Troponin T of I or CK-MB above
             the upper limit of normal for the local institution and/or (2) ECG changes compatible
             with ischemia

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 21 years

          -  Any contraindication to low molecular weight heparin

          -  Hemorrhagic stroke within the last 12 months

          -  Indication for anticoagulation other than ACS.

          -  Pregnancy or women of childbearing potential who are not using an effective method of
             contraception

          -  Co-morbid condition with life expectancy less than 6 months

          -  Prior enrollment in one of the fondaparinux ACS trails or currently receiving an
             experimental pharmacologic agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <results_reference>
    <citation>Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 Apr 6;354(14):1464-76. Epub 2006 Mar 14.</citation>
    <PMID>16537663</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unstable angina</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>fondaparinux sodium</keyword>
  <keyword>non ST segment elevation myocardial infarction</keyword>
  <keyword>myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>103420</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

